Genetic Control of Wayward Pluripotent Stem Cells and Their Progeny after Transplantation

Maija Kiuru, Julie L. Boyer, Timothy P. O'Connor, Ronald Crystal

Research output: Contribution to journalReview article

59 Citations (Scopus)

Abstract

The proliferative capacity of pluripotent stem cells and their progeny brings a unique aspect to therapeutics, in that once a transplant is initiated the therapist no longer has control of the therapy. In the context of the recent FDA approval of a human ESC trial and report of a neuronal-stem-cell-derived tumor in a human trial, strategies need to be developed to control wayward pluripotent stem cells. Here, we focus on one approach: direct genetic modification of the cells prior to transplantation with genes that can prevent the adverse events and/or eliminate the transplanted cells and their progeny.

Original languageEnglish
Pages (from-to)289-300
Number of pages12
JournalCell Stem Cell
Volume4
Issue number4
DOIs
Publication statusPublished - 3 Apr 2009
Externally publishedYes

Fingerprint

Pluripotent Stem Cells
Transplantation
Neoplastic Stem Cells
Transplants
Therapeutics
Genes

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cell Biology

Cite this

Genetic Control of Wayward Pluripotent Stem Cells and Their Progeny after Transplantation. / Kiuru, Maija; Boyer, Julie L.; O'Connor, Timothy P.; Crystal, Ronald.

In: Cell Stem Cell, Vol. 4, No. 4, 03.04.2009, p. 289-300.

Research output: Contribution to journalReview article

Kiuru, Maija ; Boyer, Julie L. ; O'Connor, Timothy P. ; Crystal, Ronald. / Genetic Control of Wayward Pluripotent Stem Cells and Their Progeny after Transplantation. In: Cell Stem Cell. 2009 ; Vol. 4, No. 4. pp. 289-300.
@article{97a59125185240a5b688069b360dae55,
title = "Genetic Control of Wayward Pluripotent Stem Cells and Their Progeny after Transplantation",
abstract = "The proliferative capacity of pluripotent stem cells and their progeny brings a unique aspect to therapeutics, in that once a transplant is initiated the therapist no longer has control of the therapy. In the context of the recent FDA approval of a human ESC trial and report of a neuronal-stem-cell-derived tumor in a human trial, strategies need to be developed to control wayward pluripotent stem cells. Here, we focus on one approach: direct genetic modification of the cells prior to transplantation with genes that can prevent the adverse events and/or eliminate the transplanted cells and their progeny.",
author = "Maija Kiuru and Boyer, {Julie L.} and O'Connor, {Timothy P.} and Ronald Crystal",
year = "2009",
month = "4",
day = "3",
doi = "10.1016/j.stem.2009.03.010",
language = "English",
volume = "4",
pages = "289--300",
journal = "Cell Stem Cell",
issn = "1934-5909",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - Genetic Control of Wayward Pluripotent Stem Cells and Their Progeny after Transplantation

AU - Kiuru, Maija

AU - Boyer, Julie L.

AU - O'Connor, Timothy P.

AU - Crystal, Ronald

PY - 2009/4/3

Y1 - 2009/4/3

N2 - The proliferative capacity of pluripotent stem cells and their progeny brings a unique aspect to therapeutics, in that once a transplant is initiated the therapist no longer has control of the therapy. In the context of the recent FDA approval of a human ESC trial and report of a neuronal-stem-cell-derived tumor in a human trial, strategies need to be developed to control wayward pluripotent stem cells. Here, we focus on one approach: direct genetic modification of the cells prior to transplantation with genes that can prevent the adverse events and/or eliminate the transplanted cells and their progeny.

AB - The proliferative capacity of pluripotent stem cells and their progeny brings a unique aspect to therapeutics, in that once a transplant is initiated the therapist no longer has control of the therapy. In the context of the recent FDA approval of a human ESC trial and report of a neuronal-stem-cell-derived tumor in a human trial, strategies need to be developed to control wayward pluripotent stem cells. Here, we focus on one approach: direct genetic modification of the cells prior to transplantation with genes that can prevent the adverse events and/or eliminate the transplanted cells and their progeny.

UR - http://www.scopus.com/inward/record.url?scp=62949195751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62949195751&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2009.03.010

DO - 10.1016/j.stem.2009.03.010

M3 - Review article

C2 - 19341619

AN - SCOPUS:62949195751

VL - 4

SP - 289

EP - 300

JO - Cell Stem Cell

JF - Cell Stem Cell

SN - 1934-5909

IS - 4

ER -